TP53 and acute myeloid leukemia: While age itself is not a specific reason to defer intensive chemotherapy, older patients in general have more high-risk features, such as AML with myelodysplasia-related changes (AML-MRC) therapy-related AML (t-AML), complex karyotype or TP53 mutation [6], and are less likely to respond to chemotherapy.